Xlife Sciences AG

  • ISIN: CH0461929603
  • Land: Schweiz

Nachricht vom 14.02.2020 | 14:14

Xlife Sciences AG: Capital Increase 'Private Placement'

Xlife Sciences AG / Key word(s): Capital Increase
Xlife Sciences AG: Capital Increase 'Private Placement'

14-Feb-2020 / 14:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Xlife Sciences AG: Capital Increase 'Private Placement'

Based on the resolution of the Board of Directors on 14th of February 2020 (resolution of the general assembly on 25th of October 2018), Xlife Sciences AG has decided to execute a "private placement" from authorized capital, 260'000 shares at a share price of CHF 33.50.- (EUR 30.70.-, average share price over the 30 last trading days, EUR/CHF average rate ESTV 1.0912). Xlife Sciences AG will direct more investments towards employees in research and development. In addition, the project portfolio will be further diversified.

Xlife Sciences AG

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch


14-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
<

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

Aktueller Webcast

home24 SE

Trading Update FY 2019

11. Februar 2020

Aktuelle Research-Studie

Original-Research: GBC Mittelstandsanleihen Index (von GBC AG): GBC Mittelstandsanleihen Index

17. Februar 2020